<- Go Home
CorMedix Inc.
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
Market Cap
$885.6M
Volume
2.0M
Cash and Equivalents
$48.5M
EBITDA
$108.2M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$202.1M
Profit Margin
94.31%
52 Week High
$17.43
52 Week Low
$5.60
Dividend
N/A
Price / Book Value
2.35
Price / Earnings
4.99
Price / Tangible Book Value
-26.37
Enterprise Value
$978.8M
Enterprise Value / EBITDA
9.02
Operating Income
$104.0M
Return on Equity
75.08%
Return on Assets
15.68
Cash and Short Term Investments
$55.7M
Debt
$148.9M
Equity
$374.1M
Revenue
$214.3M
Unlevered FCF
$17.3M
Sector
Pharmaceuticals
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium